Induced pluripotent stem cell-derived monocytic cell lines from a NOMID patient serve as a screening platform for modulating NLRP3 inflammasome activity

• Ryosuke Seki,

  Roles Conceptualization, Investigation, Writing – original draft

  Affiliations Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan, Nippon Shinyaku, CO., LTD., Kyoto, Japan

  ⨯
• Akira Ohta,

  Roles Data curation, Methodology, Resources

  Affiliation Department of Fundamental Cell Technology, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan

  ⨯
• Akira Niwa,

  Roles Investigation, Supervision

  Affiliation Nippon Shinyaku, CO., LTD., Kyoto, Japan

  ⨯
• Yoshinori Sugimine,

  Roles Investigation

  Affiliations Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan, Department of Pediatrics, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan

  ⨯
• Haruna Naito,

  Roles Supervision

  Affiliation Nippon Shinyaku, CO., LTD., Kyoto, Japan

  ⨯
• Tatsutoshi Nakahata,

  Roles Supervision

  Affiliation Department of Fundamental Cell Technology, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan

  ⨯
• Megumu K. Saito

  Roles Conceptualization, Data curation, Funding acquisition, Supervision, Writing – review & editing

  * E-mail: msaito@cira.kyoto-u.ac.jp

  Affiliation Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan

  http://orcid.org/0000-0001-8813-3614

  ⨯